We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Celcuity Inc is clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic (Rx) and companion diagnostic (CDx) strategy. The company's drug candidate, gedatolisib, is a potent, well-tolerated, small molecule dual inhibitor, administered ... Celcuity Inc is clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic (Rx) and companion diagnostic (CDx) strategy. The company's drug candidate, gedatolisib, is a potent, well-tolerated, small molecule dual inhibitor, administered intravenously, that selectively targets all class I isoforms of PI3K and mammalian target of rapamycin (mTOR). Show more
The Phase 3 VIKTORIA-1 trial remains on track to report topline data from PIK3CA wild type patient sub-group in the second half of 2024First patient dosed in a Phase 1b/2 clinical trial evaluating...
MINNEAPOLIS, May 08, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that...
MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that...
Dosed the first patient in a Phase 1b/2 trial evaluating gedatolisib in combination with darolutamide for the treatment of metastatic castration resistant prostate cancer Presented nonclinical...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.28 | -7.78588807786 | 16.44 | 16.6093 | 15.08 | 98409 | 15.65789186 | CS |
4 | -0.68 | -4.29292929293 | 15.84 | 19.725 | 15.08 | 173809 | 16.96903546 | CS |
12 | -3.25 | -17.6534492124 | 18.41 | 22.188 | 14.63 | 242249 | 17.87380133 | CS |
26 | 0.66 | 4.55172413793 | 14.5 | 22.188 | 13.48 | 201556 | 16.64615577 | CS |
52 | 4.38 | 40.6307977737 | 10.78 | 22.188 | 8.389 | 138176 | 14.9528428 | CS |
156 | -12.34 | -44.8727272727 | 27.5 | 33.01 | 4.81 | 88002 | 14.40143689 | CS |
260 | -7.33 | -32.5922632281 | 22.49 | 33.01 | 4.03 | 77392 | 16.40448073 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions